Kymera Therapeutics’ KT-621 Shows Promising Potential, Upgraded to Overweight with $79 Target

Kymera Therapeutics (KYMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Vikram Purohit from Morgan Stanley upgraded the rating on the stock to a Buy and gave it a $79.00 price target.

Vikram Purohit has given his Buy rating due to a combination of factors that highlight the promising potential of Kymera Therapeutics’ STAT6 degrader, KT-621. The recent Phase I clinical trial data demonstrated that KT-621 achieved significant target degradation in both blood and skin, with safety profiles comparable to placebo, which enhances confidence in its therapeutic viability.
Moreover, the successful results from the trial suggest that KT-621 could effectively compete in large immunology and inflammation indications, bolstering the overall prospects of Kymera’s platform. This positive outcome is considered a critical de-risking event for the company’s pipeline, prompting an upgrade to an Overweight rating with a price target of $79, as the company approaches a period rich with potential catalysts in 2025 and 2026.

In another report released today, Citi also maintained a Buy rating on the stock with a $60.00 price target.